Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 425-432

  McCafferty, Marc P J ^a   McNeill, Roisin E ^a   Miller, Nicola ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor cofactors; Estrogen receptors; MicroRNAs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CONFORMATIONAL TRANSITION; DISEASE FREE SURVIVAL; DRUG METABOLISM; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 70349576204     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0429-7     Document Type: Review

References (82)

1. W.H.O. (2006) Fact Sheet No.297. In: World Health Organisation
2. Conneely OM, Jericevic BM, Lydon JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8(2):205-214. doi:10.1023/A:1025952924864
3. Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 27:135-145
4. Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182, 780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89(4):817-825. doi:10.1002/1097-0142(20000815)89:4\817::AID-CNCR14[3.0.CO;2-6
5. Lonard DM, O'Malley BW (2006) The expanding cosmos of nuclear receptor coactivators. Cell 125(3):411-414. doi:10.1016/j.cell.2006.04.021
6. O'Malley BW (2007) Coregulators: from whence came these "master genes". Mol Endocrinol 21(5):1009-1013. doi:10.1210/me.2007-0012
7. Perissi V, Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6(7):542-554. doi:10.1038/nrm1680
8. Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14(2):121-141
9. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG (2004) A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116(4):511-526. doi:10.1016/S0092- 8674(04)00133-3
10. Privalsky ML (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66:315-360. doi:10.1146/annurev.physiol.66.032802.155556
11. Freiman RN, Tjian R (2003) Regulating the regulators: lysine modifications make their mark. Cell 112(1):11-17. doi:10.1016/S0092-8674(02) 01278-3
12. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074-1080. doi:10.1126/science.1063127
13. Tsai CC, Fondell JD (2004) Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam Horm 68:93-122. doi:10.1016/S0083-6729(04)68003-4
14. Stallcup MR, Kim JH, Teyssier C, Lee YH, Ma H, Chen D (2003) The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol 85(2-5):139-145. doi:10.1016/S0960-0760(03)00222-X
15. Lonard DM, Lanz RB, O'Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28(5):575-587. doi:10.1210/er.2007-0012
16. Hu X, Lazar MA (2000) Transcriptional repression by nuclear hormone receptors. Trends endocrinol metab: TEM 11(1):6-10
17. Jepsen K, Rosenfeld MG (2002) Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci 115(Pt 4):689-698
18. Urnov FD, Wolffe AP, Guschin D (2001) Molecular mechanisms of corepressor function. Curr Top Microbiol Immunol 254:1-33
19. Ordentlich P, Downes M, Evans RM (2001) Corepressors and nuclear hormone receptor function. Curr Top Microbiol Immunol 254:101-116
20. Goodson M, Jonas BA, Privalsky MA (2005) Corepressors: custom tailoring and alterations while you wait. Nucl recept signal 3:e003
21. Lazar MA (2003) Nuclear receptor corepressors. Nucl recept signal 1:e001
22. den Hollander P, Rayala SK, Coverley D, Kumar R (2006) Ciz1, a novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. Cancer Res 66(22): 11021-11029. doi:10.1158/0008-5472.CAN- 06-2336
23. Klinge CM (2000) Estrogen receptor interaction with co-activators and co-repressors. Steroids 65(5):227-251. doi:10.1016/S0039-128X(99)00107-5
24. Onate SA, Tsai SY, Tsai MJ, O'Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270(5240):1354-1357. doi:10.1126/science.270.5240.1354
25. Yan J, Tsai SY, Tsai MJ (2006) SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27(4):387-394. doi:10.1111/j.1745-7254.2006. 00315.x
26. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277(5328):965-968. doi:10.1126/ science.277.5328.965
27. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6(3):263-274. doi:10.1016/j.ccr.2004.06.027
28. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW (2004) Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 15(6):937-949. doi:10.1016/j.molcel.2004. 08.019
29. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT (2001) Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 68(1):21-28. doi:10.1023/A:1017910924390
30. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, Theillet C (1998) In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4(12):2925-2929
31. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R 3rd, Atkins GB, Lazar MA, Yeldandi AV, Rao MS, Reddy JK (1999) Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 96(19):10848-10853. doi:10.1073/pnas.96. 19.10848
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235(4785):177-182
33. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353-361
34. Font de Mora J, Brown M (2000) AIB1 is a conduit for kinasemediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20(14):5041-5047. doi:10.1128/MCB.20.14.5041-5047.2000
35. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747-752. doi:10.1038/35021093
36. Sorlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40(18):2667-2675. doi:10.1016/j.ejca. 2004.08.021
37. Adams BD, Furneaux H, White BA (2007) The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptoralpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21(5):1132-1147. doi:10.1210/me.2007-0022
38. Jordan VC (1993) Fourteenth Gaddum memorial lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110(2):507-517
39. EBCTCG (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351(9114):1451-1467. doi:10.1016/S0140-6736(97)11423-4
40. EBCTCG (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339(8785):71-85
41. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609-1618. doi:10.1056/NEJM1998 11263392207
42. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062-1075. doi:10.1124/jpet.104.065607
43. Wang DY, Fulthorpe R, Liss SN, Edwards EA (2004) Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol endocrinol (Baltimore MD) 18(2):402-411
44. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61-74. doi:10.1016/j.clpt.2006.03. 013
45. Jordan VC, O'Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25(36):5815-5824. doi:10.1200/JCO.2007.11.3886
46. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol endocrinol (Baltimore MD) 11(6):693-705
47. Smith CL, Nawaz Z, O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol endocrinol (Baltimore D) 11(6):657-666
48. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB (2000) Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol 74(5):255-259. doi:10.1016/S0960-0760(00)00101-1
49. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J et al (1998) Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes. Proc Natl Acad Sci USA 95(6):2920-2925. doi:10.1073/pnas.95.6.2920
50. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9(4):1259-1266
51. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill AD, Young LS (2004) Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer: a predictive role for SRC-1. J Clin Pathol 57(10):1069-1074. doi:10.1136/jcp.2004.016733
52. Razandi M, Pedram A, Park ST, Levin ER (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278(4):2701-2712. doi:10.1074/jbc.M205692200
53. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2- positive breast cancer. J Natl Cancer Inst 96(12):926-935
54. Ambros V (2001) microRNAs: tiny regulators with great potential. Cell 107(7):823-826. doi:10.1016/S0092-8674(01)00616-X
55. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281-297. doi:10.1016/S0092-8674(04)00045-5
56. Griffiths-Jones S (2004) The microRNA registry. Nucleic Acids Res 32(Database issue):D109-D111. doi:10.1093/nar/gkh023
57. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, PedrialiM, FabbriM,CampiglioMet al (2005)MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070. doi:10.1158/0008-5472.CAN- 05-1783
58. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261. doi:10.1073/pnas.0510565103
59. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C (2006) Optimized highthroughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24. doi:10.1186/1476-4598-5-24
60. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8(10):R214. doi:10.1186/gb-2007-8-10-r214
61. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34(Database issue):D140-D144. doi:10.1093/nar/gkj112
62. Hossain A, Kuo MT, Saunders GF (2006) Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26(21):8191-8201
63. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR et al (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103(24):9136-9141. doi:10.1073/pnas.0508889103
64. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M et al (2005) Combinatorial microRNA target predictions. Nat Genet 37(5):495-500. doi:10.1038/ng1536
65. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857-866. doi:10.1038/nrc1997
66. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. NatRev Cancer 6(4):259-269. doi:10.1038/nrc1840
67. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838. doi:10.1038/nature03702
68. Lowery AJ, Miller N, McNeill RE, Kerin MJ (2008) MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 14(2):360-365. doi:10.1158/1078-0432.CCR-07-0992
69. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNAbased therapeutics. Nat Rev Drug Discov 6(6):443-453. doi:10.1038/nrd2310
70. Check E (2005) A crucial test. Nat Med 11(3):243-244. doi:10.1038/nm0305-243
71. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59(2-3):75-86. doi:10.1016/j.addr.2007.03.005
72. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711-719. doi:10.1038/nchembio839
73. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Natl Rev 8(3):173-184. doi:10.1038/nrg2006
74. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897-29903. doi:10.1074/jbc. M804612200
75. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O (2007) Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619(1-2):30-37. doi:10.1016/j.mrfmmm. 2006.12.006
76. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ (2007) MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 67(23):11111-11116. doi:10.1158/0008-5472.CAN-07- 2858
77. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2007) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283(2):1026-1033
78. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647-658. doi:10.1053/j.gastro. 2007.05.022
79. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19):14328-14336. doi:10.1074/jbc.M611393200
80. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029-6033. doi:10.1158/0008-5472.CAN-05-0137
81. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130(7): 2113-2129. doi:10.1053/j.gastro.2006.02.057
82. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV et al (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68(2):425-433. doi:10.1158/0008-5472.CAN-07-2488